Cancer immunotherapy from biology to nanomedicine

Abdelbaky, Salma; Ibrahim, Mayar Tarek; Samy, Hebatallah; Mohamed, M. Sheikh; Mohamed, Hebatallah; Mustafa, Mahmoud; Abdelaziz, Moustafa M.; Forrest, M. Laird; Khalil, Islam A.

doi:10.1016/j.jconrel.2021.06.025

Cited by 18 publications

(8 citation statements)

References 262 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, immunotherapy has developed rapidly and gradually matured, and its emergence has revolutionized the treatment standard and treatment concept of cancer ( Abdelbaky et al, 2021 ; Aktar et al, 2022 ). Radiotherapy and chemotherapy of traditional treatment methods generally use toxic drugs or radiation to directly ablate cancer cells.…”

Section: Immunotherapeutic Nanomedicinementioning

confidence: 99%

Application Perspectives of Nanomedicine in Cancer Treatment

et al. 2022

View full text Add to dashboard Cite

Cancer is a disease that seriously threatens human health. Based on the improvement of traditional treatment methods and the development of new treatment modes, the pattern of cancer treatment is constantly being optimized. Nanomedicine plays an important role in these evolving tumor treatment modalities. In this article, we outline the applications of nanomedicine in three important tumor-related fields: chemotherapy, gene therapy, and immunotherapy. According to the current common problems, such as poor targeting of first-line chemotherapy drugs, easy destruction of nucleic acid drugs, and common immune-related adverse events in immunotherapy, we discuss how nanomedicine can be combined with these treatment modalities, provide typical examples, and summarize the advantages brought by the application of nanomedicine.

show abstract

Section: Immunotherapeutic Nanomedicinementioning

confidence: 99%

Application Perspectives of Nanomedicine in Cancer Treatment

et al. 2022

View full text Add to dashboard Cite

show abstract

“…At the same time, the specificity for tumor cells prevents the interactions of NPs with healthy tissues, thus reducing side effects. In addition, these systems are able to protect themselves from degradation in vivo, prolonging their availability [1]. Thus, the choice of an appropriate nanocarrier is based on the more suitable application.…”

Section: Figurementioning

confidence: 99%

“…Delivering drugs loaded inside NPs to cancer cells is a highly complicated process. Perhaps the right attitude could be to embrace the benefits of nanotechnologies but acknowledge their limitations [1]; indeed, it is necessary that NPs evade immune surveillance by avoiding opsonization by serum proteins and selectively extravasate at the tumor site [14][15][16]. Among the essential NPs' features to achieve homogeneous distribution throughout a tumor, there is the ability to overcome thick tumor stroma, uptake by macrophages, high interstitial fluid pressure, and slow diffusion [17].…”

Section: Nanocarriers As Delivery Platformsmentioning

confidence: 99%

See 1 more Smart Citation

Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies

Grimaldi

Toffoli

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Nanoparticle-based therapies have been proposed in oncology research using various delivery methods to increase selectivity toward tumor tissues. Enhanced drug delivery through nanoparticle-based therapies could improve anti-tumor efficacy and also prevent drug resistance. However, there are still problems to overcome, such as the main biological interactions of nanocarriers. Among the various nanostructures for drug delivery, drug delivery based on polymeric nanoparticles has numerous advantages for controlling the release of biological factors, such as the ability to add a selective targeting mechanism, controlled release, protection of administered drugs, and prolonging the circulation time in the body. In addition, the functionalization of nanoparticles helps to achieve the best possible outcome. One of the most promising applications for nanoparticle-based drug delivery is in the field of onco-hematology, where there are many already approved targeted therapies, such as immunotherapies with monoclonal antibodies targeting specific tumor-associated antigens; however, several patients have experienced relapsed or refractory disease. This review describes the major nanocarriers proposed as new treatments for hematologic cancer, describing the main biological interactions of these nanocarriers and the related limitations of their use as drug delivery strategies.

show abstract

“…Surgical resection combined with systemic chemotherapy is the cornerstone of localized cancer therapy. The cytotoxic effects of chemotherapy, the primary component of combination treatment, not only affect cancerous cells but also harm healthy cells, leading to drug resistance and adverse reactions [3][4][5][6]. Extended chemotherapy regimens may result in drug resistance, causing cancer cells to become tolerant to chemotherapeutic drugs, necessitating higher doses for therapeutic effectiveness, a situation that may be exacerbated by increased toxicity [6].…”

Section: Introductionmentioning

confidence: 99%

Anticancer Mechanism of Astragalus Polysaccharide and Its Application in Cancer Immunotherapy

He,

Liu,

Qin

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Astragalus polysaccharide (APS) derived from A. membranaceus plays a crucial role in traditional Chinese medicine. These polysaccharides have shown antitumor effects and are considered safe. Thus, they have become increasingly important in cancer immunotherapy. APS can limit the spread of cancer by influencing immune cells, promoting cell death, triggering cancer cell autophagy, and impacting the tumor microenvironment. When used in combination with other therapies, APS can enhance treatment outcomes and reduce toxicity and side effects. APS combined with immune checkpoint inhibitors, relay cellular immunotherapy, and cancer vaccines have broadened the application of cancer immunotherapy and enhanced treatment effectiveness. By summarizing the research on APS in cancer immunotherapy over the past two decades, this review elaborates on the anticancer mechanism of APS and its use in cancer immunotherapy and clinical trials. Considering the multiple roles of APS, this review emphasizes the importance of using APS as an adjunct to cancer immunotherapy and compares other polysaccharides with APS. This discussion provides insights into the specific mechanism of action of APS, reveals the molecular targets of APS for developing effective clinical strategies, and highlights the wide application of APS in clinical cancer therapy in the future.

show abstract

Cancer immunotherapy from biology to nanomedicine

Cited by 18 publications

References 262 publications

Application Perspectives of Nanomedicine in Cancer Treatment

Application Perspectives of Nanomedicine in Cancer Treatment

Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies

Anticancer Mechanism of Astragalus Polysaccharide and Its Application in Cancer Immunotherapy

Contact Info

Product

Resources

About